BioCompounding

Equity Analyst. We publish one deep dive on a life sciences company every month | Subscribe:

[BioCompounding @BioCompounding]

https://t.co/hnePXxYhog

[BioCompounding @BioCompounding]

Just opened up my previous deep dive and valuation analysis for all free members for $ISRG. Write ups are from back in 2023.

Updated write ups to come by end of next week.

Check them out below
https://t.co/F7cUiEQVfF

[BioCompounding @BioCompounding]

Pharma companies processed 5M data points/year in 2008. Today: 8 billion.

One Phase III trial alone generates 5.9M data points. That's a 600% surge.

This is why $VEEV exists — and why switching away from it is nearly impossible.

Read it all here!
https://t.co/DetNfcwae1

[BioCompounding @BioCompounding]

@JKeynesAlpha Wrote a deep dive on it as well. Read it here: https://t.co/GzwnFLkepq

[BioCompounding @BioCompounding]

Read the full deep dive here:
https://t.co/GzwnFLkepq

[BioCompounding @BioCompounding]

The SaaSpocalypse is ending and $VEEV surged 10%

$VEEV has compounded free cash flow at 29% annually for 10 years

The market is pricing in ~3% FCF growth going forward.
That's mis-pricing, not a discount

Revenue doubles by 2030, the math doesn't add up.

Full deep dive below!

[BioCompounding @BioCompounding]

Read the full deep dive here: https://t.co/GzwnFLkepq

[BioCompounding @BioCompounding]

$VEEV stock implies the market expects ~3.4% FCF growth over the next 5 yrs.

Veeva has compounded FCF at 29% annually for the past decade and management is targeting $6B in revenue by 2030, double today.

The market is pricing near-stagnation for pharma tech's best compounders.

[BioCompounding @BioCompounding]

@OptionWell Thanks @OptionWell. Curious how do you manage positions that go against you?

Eg. if the stock price of a covered call drops below your purchase price what is the next step?
Similarly if the short put is deep in the money?

Thanks.

[BioCompounding @BioCompounding]

In 1941, a surgeon got frustrated with his hospital bed.

So he built a better one.

That surgeon was Homer Stryker.

The company he founded just crossed $25 billion in annual revenue.

But here's what most investors are missing about $SYK in 2026.
🧵

[BioCompounding @BioCompounding]

@OptionWell Thanks that’s clear. So how you do balance delta and yield when picking a strike?

[BioCompounding @BioCompounding]

You can now track my full healthcare portfolio on Savvy Trader!

https://t.co/y0LrWDhG5E

If you sign up there write to me and I will give you free access to our research platform as well.

[BioCompounding @BioCompounding]

Anyone have a view on $INCY? Any good material I can read?

[BioCompounding @BioCompounding]

@ThainRos $SYK FCF compounding at close to 12-13% over the last 10 years. So definitely growing. Peers are a mixed bag, so far $SYK seems to be the best in class for medtech.

[BioCompounding @BioCompounding]

Most people think Stryker is just a knee and hip replacement company.

It's not.

At its core, Stryker is building the most valuable data asset in surgical medicine, one procedure at a time.

I wrote a full deep dive on $SYK https://t.co/DAgeJB9MhP

[BioCompounding @BioCompounding]

The company I think is best positioned to compound through this wave?

$SYK — Stryker.

I wrote a full deep dive on $SYK, $ISRG, $MDT you can read it on all on - https://t.co/kjcy8hzGSA

Who else are you backing to ride the ageing wave?

[BioCompounding @BioCompounding]

The biggest investment trend of the next 30 years isn't AI.

It's this: The world is running out of young people

→ 850M people are over 65 today
→ That number doubles to 1.7B by 2054
→ By 2030, 1 in 6 humans will be over 60
→ The number of 80+ year olds triples by 2050

[BioCompounding @BioCompounding]

We're just living through the early innings.

Japan figured this out first. 30% of their population is already over 65. Their medtech market has quietly outgrown their pharma market for years.

Europe is next. Then the US. Then the rest of the world.

[BioCompounding @BioCompounding]

One question for the room:

Which other companies are you backing to compound through that wave?

[BioCompounding @BioCompounding]

In 1941, a surgeon got frustrated with his hospital bed.

So he built a better one.

That surgeon was Homer Stryker.

The company he founded just crossed $25 billion in annual revenue.

But here's what most investors are missing about $SYK in 2026.
🧵

[BioCompounding @BioCompounding]

Read the full deep dive 👇
https://t.co/DAgeJB9MhP

Which covers the data flywheel, the Smart Hospital platform, the reverse DCF, and why what happened in Japan is about to happen everywhere.